.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,283,209

« Back to Dashboard
Patent 9,283,209 protects JADENU and is included in one NDA. There have been two Paragraph IV challenges on Jadenu.

This patent has twenty-one patent family members in twenty-one countries.

Summary for Patent: 9,283,209

Title:Oral formulations of deferasirox
Abstract: Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.
Inventor(s): Ghosh; Indrajit (Hillsborough, NJ), Zhang; Jia-Ai (Skillman, NJ)
Assignee: NOVARTIS AG (Basel, CH)
Application Number:14/198,872
Patent Claim Types:
see list of patent claims
Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
JADENU
deferasirox
TABLET;ORAL206910-001Mar 30, 2015RXNo9,283,209► subscribeYY
Novartis Pharms Corp
JADENU
deferasirox
TABLET;ORAL206910-002Mar 30, 2015RXNo9,283,209► subscribeYY
Novartis Pharms Corp
JADENU
deferasirox
TABLET;ORAL206910-003Mar 30, 2015RXYes9,283,209► subscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,283,209

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina095058► subscribe
Australia2014224198► subscribe
Canada2890465► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc